Who Paid My Doc
Douglas Blacklidge
Podiatrist, Foot & Ankle Surgery Kokomo, IN Doctor of Podiatric Medicine
NPI 1003901133 CMS profile 359
2341 W Lincoln Rd, Kokomo, IN 46902
General payments
$688,538
Research payments
$0
Ownership & investment interest
$1,232,893
Through program year 2025, Douglas Blacklidge of Kokomo, IN is reported in the CMS Open Payments database as having received $688,538 across 297 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,232,893 across 4 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $43,805 | 38 | |
| 2024 | General | $84,512 | 32 | |
| 2023 | General | $80,588 | 30 | |
| 2022 | General | $134,962 | 53 | |
| 2021 | General | $121,818 | 43 | |
| 2020 | General | $102,621 | 37 | |
| 2019 | General | $120,233 | 64 | |
| 2020 | Ownership | $616,446 | 2 | |
| 2019 | Ownership | $616,446 | 2 |
Beside peers
- Douglas Blacklidge
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to Douglas Blacklidge were reported at $43,805. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | Douglas Blacklidge | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $120,233 | $389 | $118–$1,406 | $163 |
| 2020 | $102,621 | $191 | $62–$691 | $114 |
| 2021 | $121,818 | $329 | $104–$1,341 | $132 |
| 2022 | $134,962 | $419 | $125–$1,611 | $149 |
| 2023 | $80,588 | $377 | $128–$1,164 | $160 |
| 2024 | $84,512 | $394 | $134–$1,168 | $164 |
| 2025 | $43,805 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
349
Drug cost
$4,247
Branded share of claims
36.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Febuxostat | Generic | 19 | $931 | |
| Gabapentin | Generic | 38 | $557 | |
| Terbinafine Hcl | Generic | 16 | $474 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 70 | $454 | |
| Celecoxib | Generic | 14 | $421 | |
| Ciclopirox Ciclopirox Olamine | Brand | 26 | $420 | |
| Allopurinol | Generic | 61 | $291 | |
| Cephalexin | Generic | 35 | $239 | |
| Methylprednisolone | Generic | 26 | $177 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 14 | $166 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 85 billing codesPaid by Medicare
$100,712
Medicare patients
363
Services billed
1,336
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Diabetes | 33% | |
| Chronic kidney disease | 27% | |
| Ischemic heart disease | 26% | |
| Depression | 25% | |
| Atrial fibrillation | 19% | |
| Heart failure | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 39 | 50 | $34 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
297 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Indiana
Patrick Deheer
Podiatrist, Foot & Ankle Surgery · Indianapolis, IN
Scott Neville
Podiatrist, Foot & Ankle Surgery · Mooresville, IN
Travis Montgomery
Podiatrist, Foot & Ankle Surgery · Westfield, IN
Robert Clemency III
Podiatrist, Foot & Ankle Surgery · Schererville, IN
William Adams
Podiatrist, Foot & Ankle Surgery · Greenfield, IN
Steven Douthett
Podiatrist, Foot & Ankle Surgery · Fort Wayne, IN
Related records
Podiatrist, Foot & Ankle Surgery in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.